CHA₂DS₂-VASc Calculator
Add the eight established thromboembolic risk components for a person with documented atrial fibrillation, expose every single and doubled point, and frame the result with 2023 U.S. guideline thresholds.
Enter the documented AF profile
What each letter contributes
C: congestive heart failure or left-ventricular dysfunction, 1. H: hypertension, 1. A₂: age 75 or older, 2. D: diabetes mellitus, 1. S₂: prior stroke, transient ischemic attack, or thromboembolism, 2. V: vascular disease, 1. A: age 65–74, 1. Sc: female sex category, 1.
The two age rows are mutually exclusive. A 78-year-old gets 2 for age, not 2 plus 1. The two “2” components—older age and previous cerebral/systemic thromboembolism—explain why the acronym contains subscripts.
Definitions should come from the medical record and the governing guideline. A single elevated blood-pressure reading does not necessarily establish a history of hypertension, and nonspecific leg pain does not establish peripheral artery disease.
Worked female age-68 score of 4
The default profile has documented AF, female sex category, age 68, hypertension, and vascular disease. There is no selected heart failure, diabetes, previous stroke/TIA/systemic embolism, rheumatic mitral stenosis, or mechanical valve.
Hypertension adds 1. Age 68 is in the 65–74 bracket and adds 1. Vascular disease adds 1. Female sex category adds 1. The total is 4, and the score excluding sex category is 3. Neither doubled component is present.
Under the 2023 ACC/AHA/ACCP/HRS guideline, a CHA₂DS₂-VASc score of at least 3 in women is an example of an estimated annual thromboembolic risk of at least 2%, where anticoagulation is recommended to prevent stroke and systemic embolism when clinically appropriate. The score does not select a drug or quantify this individual’s exact annual rate.
2023 U.S. anticoagulation thresholds
Below intermediate example
Score 0 in men or 1 in women when the only point is sex category generally represents no non-sex risk factor. Aspirin is not an anticoagulation substitute for AF stroke prevention.
About 1% to under 2% yearly
Equivalent examples are score 1 in men and 2 in women. The guideline says anticoagulation is reasonable, requiring shared decision-making and modifiers.
At least 2% yearly
Equivalent examples are score at least 2 in men and at least 3 in women. Anticoagulation is recommended when not contraindicated.
These are guideline risk-level examples, not a claim that every person at a given score has the same rate. The guideline explicitly notes that scores applied to different cohorts yield different stroke rates.
Female sex acts as a risk modifier
Female sex alone does not create the same treatment threshold as a non-sex risk factor. That is why U.S. guideline examples are one point higher for women: 2 versus 1 in the intermediate range and 3 versus 2 in the recommended range.
The calculator therefore displays both the conventional total and the total excluding sex category. It does not erase the published Sc point, nor does it treat every female score of 1 as a high-risk state.
The variable reflects how the validated score was constructed. It is not a complete model of sex biology, gender identity, hormone exposure, or individualized risk. For transgender and intersex patients, clinicians should interpret the evidence and score limitations explicitly rather than guessing from the interface.
Document AF before using an AF stroke score
CHA₂DS₂-VASc was developed for stroke risk stratification in atrial fibrillation. Palpitations, a smartwatch alert, an irregular pulse, or sinus tachycardia does not by itself confirm AF. Diagnosis usually requires clinician-reviewed electrocardiographic evidence.
AF can be paroxysmal, persistent, long-standing persistent, or permanent. The guideline bases thromboembolic prevention on estimated risk rather than assuming brief or symptom-free AF is harmless. Device-detected atrial high-rate episodes have separate duration- and risk-based recommendations.
If AF is not documented, this calculator blocks a result. A clinician may evaluate symptoms with ECG, ambulatory monitoring, laboratory tests, echocardiography, and review of reversible contributors.
Mechanical valves and rheumatic mitral stenosis
The 2023 guideline recommends direct oral anticoagulants over warfarin for eligible AF patients except those with moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve. Those conditions require a different anticoagulant pathway.
The score can still describe risk factors, but the calculator changes its message when that switch is selected. It does not compare valve types, INR targets, bridging, procedures, pregnancy, or drug interactions.
Never replace warfarin with a DOAC, or vice versa, based on a score. Valve records, operative reports, echocardiography, indication, and specialist guidance are essential.
Stroke benefit must be weighed against bleeding
CHA₂DS₂-VASc estimates thromboembolic risk factors; it does not calculate bleeding risk. A clinician reviews previous bleeding, anemia, platelet count, kidney and liver function, blood pressure, falls, alcohol, interacting medicines, adherence, cost, and patient goals.
The 2023 guideline cautions against using bleeding risk scores in isolation to deny anticoagulation to someone at high stroke risk. Bleeding assessment should identify modifiable factors and inform monitoring and shared decisions.
Urgent evaluation is needed for severe or uncontrolled bleeding, black or bloody stool, vomiting blood, coughing blood, severe headache after a fall, sudden weakness, or other concerning symptoms while anticoagulated. Do not wait for an appointment or calculator.
Risk changes over time
Age can cross from below 65 to 65–74 and then to 75 or older. Hypertension, diabetes, heart failure, vascular disease, or a thromboembolic event can develop. A prior score is not permanent.
The AF guideline recommends periodic reassessment of stroke-prevention therapy because physiology, comorbidities, medications, bleeding risk, and preferences change. Reassessment does not mean repeatedly stopping and starting anticoagulation without supervision.
Document the score date, component definitions, AF context, current treatment, renal function, and clinical decision. A total without its components is difficult to audit and can conceal a data-entry error.
What the score leaves out
CHA₂DS₂-VASc does not include AF burden, left-atrial size and function, kidney disease as a direct point, biomarkers, obesity, sleep apnea, smoking, family history, or many imaging findings. Some factors may modify risk especially near an intermediate threshold.
It also does not predict hemorrhagic stroke, myocardial infarction, heart-failure hospitalization, AF symptoms, rhythm-control success, or all-cause mortality. The outcome and time frame must remain clear.
Alternative validated tools such as ATRIA or GARFIELD-AF may estimate risk differently. The 2023 guideline allows use of validated scores and additional modifiers; it does not claim one integer captures true individual probability.
A safe AF stroke-prevention pathway
Confirm
Verify clinician-documented AF, rhythm context, valve status, and current medication.
Score
Document every CHA₂DS₂-VASc component and keep age categories exclusive.
Balance
Review annual-risk threshold, bleeding factors, modifiers, preferences, access, and alternatives.
Reassess
Follow adherence, renal/hepatic function, bleeding, new risk factors, and procedures over time.
CHA₂DS₂-VASc checklist
- Confirm atrial fibrillation documentation.
- Record current age.
- Count only one age bracket.
- Review heart failure or LV dysfunction.
- Review hypertension history.
- Review diabetes diagnosis.
- Verify prior stroke, TIA, or embolism.
- Verify prior MI, PAD, or aortic plaque.
- Apply sex category and sex-specific threshold.
- Check mechanical valve and rheumatic stenosis.
- Do not assign one fixed annual percentage.
- Assess bleeding factors separately.
- Never substitute aspirin on your own.
- Reassess when clinical status changes.
It does not determine drug coverage, medical deductions, anticoagulant cost, stroke risk, or treatment.
Frequently asked questions
Do age 75 and age 65–74 points stack?
No. Age 75 or older gets 2; age 65–74 gets 1. The categories are mutually exclusive.
Does a woman get anticoagulation for sex category alone?
Sex alone yields a conventional score of 1 but no non-sex risk factor. U.S. thresholds are one point higher for women because sex is treated as a modifier.
Can a score tell me which blood thinner to use?
No. Valve status, kidney and liver function, bleeding, interactions, adherence, cost, and other factors determine options.
Does successful ablation erase the score?
No. The 2023 guideline bases longer-term anticoagulation after ablation on underlying stroke risk, not assumed elimination of AF alone.
Is aspirin a safer substitute?
The guideline does not recommend aspirin alone or with clopidogrel as an alternative to anticoagulation for AF stroke prevention when anticoagulation is indicated.